Prothena Corporation plc Overview
|
|
- Marion Price
- 5 years ago
- Views:
Transcription
1 November 11, 2014 Prothena Corporation plc Overview 2014 Credit Suisse HC Conference The Arizona Biltmore Phoenix, AZ
2 Forward-Looking Statements This presentation contains forward-looking statements. These statements relate to, among other things, our ability to advance and meet the expected timelines for our three lead programs, NEOD001, PRX002 and PRX003, and our ability to meet our projected cash burn, net loss and year-end cash position. These forward-looking statements are based on estimates, projections and assumptions that may prove not to be accurate, and actual results could differ materially from those anticipated due to known and unknown risks, uncertainties and other factors, including but not limited to the risks and uncertainties described in the Risk Factors sections of our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 7, 2014, and our subsequent Quarterly Reports on Form 10-Q filed with the SEC. Prothena undertakes no obligation to update publicly any forward-looking statements contained in this presentation as a result of new information, future events or changes in Prothena's expectations. 2
3 Prothena Vision We target proteins in novel ways to resolve unmet clinical need in patients 3
4 Prothena Overview Advancing and developing novel antibodies for diseases caused by amyloid or cell adhesion Team has track record of discovering and developing immunotherapy products including abeta immunotherapy and Tysabri Lead programs in the pipeline (all mabs): NEOD001, for AL amyloidosis, expected to enter P2/3 in 4Q14 PRX002, α-synuclein immunotherapy for Parkinson s disease, in Phase 1 SAD and MAD (worldwide collaboration with Roche) PRX003, anti-mcam antibody for psoriasis, expected to enter P1 SAD in 1H15 Robust cash position of $306M at end of 3Q14 4
5 R&D Pipeline for Lead Programs LEAD PROGRAM Preclinical Phase 1 Phase 2 Phase 3 COMMERCIALIZATION RIGHTS NEOD001 AL Amyloidosis Phase 1 MAD Phase 2/3 PRX002 Parkinson s Disease Phase 1 SAD Phase 1 MAD PRX003 Psoriasis Phase 1 SAD Preclinical Ongoing Planning 5
6 Upcoming Milestones NEOD001 for AL Amyloidosis New data from ongoing Phase 1 MAD study expected later in 2014 Expect to initiate Phase 2/3 trial later in 2014 PRX002 for Parkinson s disease and other related synucleinopathies (worldwide collaboration with Roche) Phase 1 SAD data in healthy subjects expected in 1H15 Phase 1 MAD data in patients expected in 2016 PRX003 for psoriasis and other inflammatory diseases Announced initial indication as a potentially rapid clinical path to proof-of-biology Expect to initiate Phase 1 SAD trial in first half 2015 Expect to initiate Phase 1 MAD trial in
7 NEOD001 for AL Amyloidosis
8 Systemic Amyloidoses are Orphan Diseases with Unmet Need and No Approved Therapies Immunotherapy mabs to treat amyloid AL amyloidosis represents majority of systemic amyloidoses (including AA and ATTR) 1 ~15,000 patients in US and Europe Does not include ~12,000 patients with multiple myeloma who also have AL amyloidosis 2 Clinical characteristics Median onset age of 60 years Affects multiple organs including heart, kidney and peripheral nerves Median cardiac survival ~1 year 3 Reducing disease progression remains significant unmet need Existing off-label therapies reduce production, but do not address resident amyloid, and have significant associated adverse events Substantial need for safe and well tolerated disease modifying therapies that improve organ function 8 1. van Gameren, I., et al. (2010) Arthritis Care Res, 62: Gertz, 2013 and Mahmood, Based on a survey of ~23 publications
9 Amyloid Deposits Buildup in Multiple Organs and Cause Organ Failure 1 HEART (50-65%) Fatigue (inability to be active) Shortness of breath (dyspnea) Irregular heart beat Fainting (syncope) Leads to congestive heart failure All patients show cardiac involvement at autopsy KIDNEYS (60-80%) Large amounts of protein in urine (proteinuria) Swelling of feet and legs End stage kidney disease Transplant can be required PERIPHERAL NERVES (20-45%) Neuropathy Impotence No temperature sensation in hands and feet OTHER ORGANS Liver (15-30%) GI Tract (5-16%) Eyes (10-25%) Tongue (~10%) Soft Tissue (20-35%) 9 1. Based on a survey of ~23 publications
10 Potential NEOD001 MOAs: Neutralizes Soluble Amyloid and Clears Insoluble Amyloid Plasma cells overproduce light chains that misfold, aggregate and become toxic amyloid NEOD001 neutralizes and disaggregates circulating soluble amyloid NEOD001 clears deposited insoluble amyloid by inducing macrophages to phagocytose amyloid NEOD001 recycled to continue neutralizing soluble amyloid and clearing deposited insoluble amyloid 10
11 Summary NEOD001 Results from Ongoing Phase 1 Trial in Patients with AL Amyloidosis Chronic monthly infusions of NEOD001 are safe and well-tolerated in AL Amyloidosis patients 18 patients enrolled in 6 dosing cohorts; 14 of 18 patients continue to receive NEOD001 (4 patients discontinued) 106 infusions administered and mean treatment duration of 6 months per patient 1 No hypersensitivity reactions No drug-related SAEs PK consistent with infusions every 28 days No anti-drug antibodies 56% cardiac response (n=5) and 33% stabilization (n=3) 2 rates Cardiac response rate compares favorably to rates in prior AL Amyloidosis study of 26% 3 Phase 1 MAD Data Supports and Informs Planned Phase 2/3 Study Equivalent to 6 infusions per patient (IV q28 days) 2. Based on Any Response criteria 3. Comenzo, et al., Leukemia. 2012;26: Unaudited interim data as of 3/11/14
12 Ongoing NEOD001 Phase 1 Trial Design Primary Objectives Secondary Objectives Evaluate the safety and tolerability of NEOD001 Determine maximum tolerated dose or Phase 2/3 recommended dose of NEOD001 Evaluate the serum pharmacokinetics (PK) of NEOD001 Assess immunogenicity of NEOD Exploratory Objectives Evaluate organ response (e.g., NT-proBNP, proteinuria and alkaline phosphatase) and hematologic response (dflc) Trial Design Multiple Ascending Dose (3+3) Up to 30 patients with AL amyloidosis 7 cohorts; IV q28 days; determine MTD/P2RD 1 mg/kg 2 mg/kg 4 mg/kg 8 mg/kg 16 mg/kg 30 mg/kg* Expansion Phase Additional patients with selected organ dysfunction 0.5 mg/kg 12 * Maximum of 2500 mg per dose permitted 24 mg/kg selected based on patient body weights Clinicaltrials.gov identifier: NCT
13 High Rate of Cardiac Biomarker Response and Stabilization in NEOD001-Treated Patients Progression 29% Stable 21% Single-Agent NEOD001 Stable 44.4% Response Response 55.6% 50% Best Response (N=9) Progression 11.1% Stable 33.3% Response 55.6% Any Response (N=9) Patients Continuing to have Cardiac Dysfunction Post-Standard of Care % of Cardiac AL Amyloidosis Patients 13 NOTE: Cardiac response defined as >30% and 300 pg/ml decrease in NT-proBNP and cardiac progression defined as >30% and 300 pg/ml increase in NT-proBNP in patients without progressive renal dysfunction with baseline NT-proBNP of 650 pg/ml. Stable is defined as being neither a responder or progressor. Interim unaudited data as of 3/11/14
14 Beneficial Changes in NT-proBNP Correlates to Mortality in Patients Heart Failure 1 AL Amyloidosis High-High 0.8 Cumulative mortality (%) Log rank test p< Low-High Low-Low Proportion surviving p<0.001 p<0.001 Response Stable 0.2 High-Low 0.1 Progression Days from randomization Time (Months) NT-proBNP progression (at least 300 ng/l and 30% increase), 169 patients NT-proBNP stable, 108 patients NT-proBNP response (at least 300 ng/l and 30% decrease), 100 people Masson, et al., Journal of the American College of Cardiology. 2008;52: Comenzo, et al., Leukemia. 2012;26:
15 PRX002 for Parkinson s Disease and Other Related Synucleinopathies (worldwide collaboration with Roche)
16 Parkinson s is a Neurodegenerative Disease with No Approved Disease-Modifying Therapies Parkinson s disease (PD) is the 2nd most common neurodegenerative disorder Current treatments manage early symptoms, not disease There are an estimated 7-10 million Parkinson s patients worldwide Genetic mutations cause early and aggressive disease Synuclein pathology strongly implicated in PD Also associated with other CNS and peripheral diseases, including some orphan indications Synuclein is the predominant component of Lewy bodies found in Parkinson s disease and other synucleinopathies 16
17 Synuclein Immunotherapy may Reduce Neuronal Toxicity and Prevent Cell-to-Cell Transfer Synaptic Loss and Pathogenic Spread Antibodies Reduce Pathogenic Spread and Decrease Synuclein Pathology 17
18 Prothena mab Reduces CNS Synuclein Pathology in Transgenic Mouse Model of Parkinson s Disease α-synuclein Pathology in the CNS 25 % area of the neuropil Control mab 0 Control mab Anti-synuclein mab Treated with Anti-Synuclein 18 Masliah (2013) First International Novartis Parkinson s Disease Symposium. Organized by Osaka University. Osaka, JAPAN
19 Lowering Synuclein with Prothena mab Protects Synapses and Improves Behavior in Transgenic Mice Synapse Protection Improved behavior in Morris Water Maze 35 % Area Synaptophysin-IR Distance (m) * Control mab * * * Wild Type P<0.05 Anti- Synuclein Training Session (day) Transgenic mice 19 Masliah (2013) First International Novartis Parkinson s Disease Symposium. Organized by Osaka University. Osaka, JAPAN
20 Worldwide PRX002 Collaboration with Roche Total Milestones $600M Upfront and near-term Clinical, regulatory and first sale Ex-U.S. sales milestones U.S. Profit & Loss Split U.S. Co-Develop U.S. Co-Promote Ex-U.S. 45M 380M 175M 30% Ability to opt-out 1 Ability to opt-in Up to double digit royalties % Will lead the clinical development Will lead the commercialization Sole responsibility to develop and commercialize Total milestones expected to more than fully fund U.S. clinical development of PRX002 Continue to participate through Joint Steering Committee $45M already received in 2014 Retain significant financial upside Ability to build U.S. specialty sales force Upon opting out of the co-development and cost and profit sharing on any co-developed Licensed Products, Prothena instead would receive U.S. commercial sales milestones totaling up to $155.0 million and tiered, single-digit to high double-digit royalties in the teens based on U.S. annual net sales, subject to certain adjustments
21 PRX002 Phase 1 SAD and MAD Studies Underway Worldwide collaboration with Roche Phase 1 SAD study in healthy subjects underway; data expected in first half 2015 Phase 1 MAD placebo-controlled double blind study in PD patients underway (n=60 patients); data expected in 2016 Biomarkers from CNS and periphery anticipated to guide Phase 2 dose selection Potential development of follow-on antibodies for other related synucleinopathies 21
22 PRX003 for Psoriasis and Other Inflammatory Diseases
23 MCAM Blockade Potentially More Effective Approach for Treating Inflammation Compared to anti-il17 Therapies IL-12 T H 1 cell Peptide-MHC molecule IL-4 T H 2 cell DC Naïve T cell TCR TGFß T Reg cell TGFß and IL-6 (IL-1 and IL-23) T H 17 cell IL17 IL22 CCL20 IL26 (IFNg) (IL6) (TNF) RORgt 23 Figure modified from: Zou & Restifo, Nature Reviews Immunology10: (2010)
24 PRX003 Clinical Trial Expected to Initiate in 2015 Selected psoriasis as a potentially rapid clinical path to proof-of-biology Expect to initiate Phase 1 SAD trial in first half 2015 Expect to initiate Phase 1 MAD trial in
25 Corporate Information
26 Financial Overview SUMMARY INFORMATION Cash and cash equivalents (September 30, 2014) $306M Shares outstanding (October 24, 2014) M 2014 GUIDANCE Net cash burn from operating activities $7 to $12M Net loss $13 to $18M Projected year-end cash position (mid-point) ~$285M Does not include 2.6mm ordinary shares underlying options with a weighted average strike price of $13.10
27 Q&A Session
Prothena Corporation plc
Prothena Corporation plc PRX003 Investor Update: Phase 2 Development Strategy September 29, 2016 Agenda Dr. Gene Kinney, Chief Operating Officer Introduction Dr. Ken Flanagan, Senior Scientist Th17 and
More informationMayo Clinic, Rochester, Minnesota; 2 Tufts Medical Center, Boston, Massachusetts; 3
NEOD001 Demonstrates Organ Biomarker Responses in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction: Final Results From a Phase 1/2 Study Morie A. Gertz, 1 Raymond L. Comenzo, 2 Heather
More informationCorporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC
Corporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts
More informationNew Approach to Parkinson s Disease: Synuclein Immunotherapy
RB2014 Conference August 22, 2014 New Approach to Parkinson s Disease: Synuclein Immunotherapy Dale Schenk, PhD President and CEO Prothena Corporation plc Primary Motor and Non-Motor Symptoms of Parkinson
More informationCAELUM BIOSCIENCES. Corporate Overview May, 2017
CAELUM BIOSCIENCES Corporate Overview May, 2017 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning
More informationDeveloping & Commercializing Targeted Small Molecule Drugs in Cancer
Developing & Commercializing Targeted Small Molecule Drugs in Cancer SAFE HARBOR STATEMENT 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationDynavax Corporate Presentation
Dynavax Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements, including statements regarding our HEPLISAV-B TM regulatory submissions, product profile,
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2016 EARNINGS PRESENTATION MARCH 2017 1 Forward-looking statements disclosure This presentation contains
More informationPioneering Precision Cardiovascular Medicine. (NASDAQ: MYOK) Corporate Presentation March 2018
Pioneering Precision Cardiovascular Medicine (NASDAQ: MYOK) Corporate Presentation March 2018 Forward-Looking Statements Statements we make in this presentation may include statements which are not historical
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationCreating a Leading Global HBV Therapeutics Company. ARB-1467 Update Call December 12, 2016
Creating a Leading Global HBV Therapeutics Company ARB-1467 Update Call December 12, 2016 NASDAQ: ABUS www.arbutusbio.com Forward Looking Statements This presentation contains forward-looking statements
More informationNEOD001 for amyloid light-chain (AL) amyloidosis
NIHR Innovation Observatory Evidence Briefing: October 2017 NEOD001 for amyloid light-chain (AL) amyloidosis NIHRIO (HSRIC) ID: 10617 NICE ID: 8803 LAY SUMMARY Amyloid light-chain (AL) amyloidosis is caused
More informationNovember 2, Q Financial Results
November 2, 2017 Q3 2017 Financial Results Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Steve Kanes, M.D., Ph.D., Chief Medical Officer
More informationDetermined to realize a future in which people with cancer live longer and better than ever before Q Conference Call
Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Q1 2016 Conference Call 1 Forward-Looking Statements Disclosure This presentation
More informationCommitted to Transforming the Treatment Paradigm for Migraine Prevention
June 14, 2018 Committed to Transforming the Treatment Paradigm for Migraine Prevention September 6, 2018 Forward-Looking Statements This presentation and the accompanying commentary contains certain forward-looking
More informationAmicus Establishes Gene Therapy Pipeline for Lysosomal Storage Disorders (LSDs) Conference Call and Webcast September 20, 2018
Amicus Establishes Gene Therapy Pipeline for Lysosomal Storage Disorders (LSDs) Conference Call and Webcast September 20, 2018 Introduction 2 Safe Harbor This presentation contains "forward-looking statements"
More informationIdenix Pharmaceuticals Building a Leading Antiviral Franchise. Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston
Idenix Pharmaceuticals Building a Leading Antiviral Franchise Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston Safe Harbor This presentation includes forward-looking statements
More informationNew Ideas. Better Medicines. Third Quarter Financial Results Conference Call
New Ideas. Better Medicines. Third Quarter 2018 Financial Results Conference Call Forward-Looking Statements 2 This presentation contains forward-looking statements that involve substantial risks and uncertainties.
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer June 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results may
More informationJuly, ArQule, Inc.
July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical
More informationConference Call to Discuss FDA Approval of ONPATTRO (patisiran)
Conference Call to Discuss FDA Approval of ONPATTRO (patisiran) August 10, 2018 1 Agenda Welcome Christine Lindenboom Vice President, Investor Relations & Corporate Communications Introduction John Maraganore,
More informationmicrorna Therapeutics Harnessing the power of micrornas to target multiple pathways of disease
microrna Therapeutics Harnessing the power of micrornas to target multiple pathways of disease January 2018 Safe Harbor Statement Statements contained in this presentation regarding matters that are not
More informationSunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results
Investor and Media Inquiries: David Pitts Argot Partners 212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals Inc. 650-266-3717 Sunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results SOUTH
More informationBuilding a Fully Integrated Biopharmaceutical Company. June 2014
Building a Fully Integrated Biopharmaceutical Company June 2014 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer January 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results
More informationMore cancer patients are being treated with immunotherapy, but
Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors PRINCETON, N.J. & SOUTH
More informationNew SEL-212 Phase 2 Data Presented at EULAR. June 15, 2018
New SEL-1 Phase Data Presented at EULAR June 15, 1 Safe Harbor / Disclaimer Any statements in this presentation about the future expectations, plans and prospects of Selecta Biosciences, Inc. ( the company
More informationCorporate Overview H.C. Wainwright & Co. Global Life Sciences Conference April 10, 2018 Douglas M. Fambrough, CEO Jack Green, CFO
NASDAQ: DRNA Corporate Overview H.C. Wainwright & Co. Global Life Sciences Conference April 10, 2018 Douglas M. Fambrough, CEO Jack Green, CFO Forward looking statements This information may contain projections
More informationDicerna Pharmaceuticals Overview. Delivering RNAi-Based Breakthrough Therapies
Pharmaceuticals Overview Delivering RNAi-Based Breakthrough Therapies Forward-Looking Statements This information may contain projections and other forward looking statements regarding future events, including
More informationJune IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs)
June 2015 IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs) 1 Forward-looking Statements This presentation contains forward-looking statements with respect to, among other things, our
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer March 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn's actual results may
More informationFive Prime Therapeutics, Inc. Corporate Overview
Five Prime Therapeutics, Inc. Corporate Overview June 2015 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities
More informationNewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results
July 31, 2015 NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results -Management to Host Conference Call Today at 8:30 a.m. ET- AMES, Iowa, July 31,
More informationCorporate Presentation August 6, 2015
Corporate Presentation August 6, 2015 Creating the Next Generation of CNS Drugs Forward-Looking Statement This presentation contains forward-looking statements. These statements relate to future events
More informationAquinox Q2 /2015 Conference Call: LEADERSHIP Secondary Endpoint Update - AQX-1125 in BPS/IC. August 6, 2015
Aquinox Q2 /2015 Conference Call: LEADERSHIP Secondary Endpoint Update - AQX-1125 in BPS/IC August 6, 2015 Forward Looking Statements / Safe Harbor This presentation and the accompanying oral commentary
More informationProthena Corporation plc R&D Day. November 16, 2017
Prothena Corporation plc R&D Day November 16, 2017 Gene Kinney, PhD President & Chief Executive Officer Forward-Looking Statements This presentation contains forward-looking statements. These statements
More informationCommitted to Transforming the Treatment Paradigm for Migraine Prevention
Committed to Transforming the Treatment Paradigm for Migraine Prevention 36th Annual J.P. Morgan Healthcare Conference January 8, 2018 Forward-Looking Statements This presentation and the accompanying
More informationArQule Jefferies Global Healthcare Conference June 2015
ArQule Jefferies Global Healthcare Conference June 2015 1 ArQule Corporate Update Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning
More informationCOMPANY OVERVIEW. June CytomX Therapeutics, Inc.
COMPANY OVERVIEW June 2016 2016 CytomX Therapeutics, Inc. Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation may contain projections and other forward-looking
More informationInducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy
Inducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy Company Overview, September 2018 Safe Harbor Statement This presentation contains forward-looking
More informationBreathtaking science. Developing respiratory drugs to improve health and quality of life. H.C. Wainwright Global Life Sciences Conference April 2018
Breathtaking science Developing respiratory drugs to improve health and quality of life H.C. Wainwright Global Life Sciences Conference April 2018 www.veronapharma.com Forward-Looking Statements This presentation
More informationBuilding a Premier Oncology Biotech
Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical
More informationInvestor Presentation March 2015
Investor Presentation March 2015 1 Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include forward-looking statements within the
More informationSupernus Pharmaceuticals
Supernus Pharmaceuticals Jefferies 2016 Healthcare Conference May 2016 1 Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include
More informationFebruary 23, Q4 and Year-End 2016 Financial Results
February 23, 2017 Q4 and Year-End 2016 Financial Results 2 RETHINKING CNS Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Jim Doherty, Ph.D.,
More informationAnti-IL-33 (ANB020) Program
Anti-IL-33 (ANB020) Program Phase 2a Peanut Allergy Clinical Trial Interim Data Update March 26 th 2018 NASDAQ: ANAB Safe Harbor Statement This presentation and the accompanying oral presentation contain
More informationFebruary 20, 2019 MANAGEMENT CALL TO DISCUSS PHASE 2 PHOENIX RESULTS AND CKD PROGRAM UPDATES
February 20, 209 MANAGEMENT CALL TO DISCUSS PHASE 2 PHOENIX RESULTS AND CKD PROGRAM UPDATES Forward-Looking Statements This presentation contains certain forward-looking statements that are made pursuant
More informationSAVARA CORPORATE PRESENTATION (NASDAQ: SVRA) NOVEMBER 2018
SAVARA CORPORATE PRESENTATION (NASDAQ: SVRA) NOVEMBER 2018 SAFE HARBOR STATEMENT Savara Inc. ( Savara or the Company ) cautions you that statements in this presentation that are not a description of historical
More informationESC 2018 Tafamidis Analyst Briefing. August 27, 2018
ESC 2018 Tafamidis Analyst Briefing August 27, 2018 1 Forward Looking Statements This presentation includes forward-looking statements about, among other things, a potential indication for Tafamidis for
More informationTargeting and Treating Cancer
Targeting and Treating Cancer Mark R. Baker, Chief Executive Officer Jefferies Healthcare Conference June 2015 Disclosure Notice This presentation may contain projections and other forward-looking statements
More informationOncology Therapeutics without Compromise APRIL 2011
Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other
More informationBioArctic AB Aktiespararna Gunilla Osswald, PhD, CEO Nasdaq Stockholm: BIOA B January 21, 2019
BioArctic AB Gunilla Osswald, PhD, CEO Aktiespararna Nasdaq Stockholm: BIOA B January 21, 2019 Disclaimer This presentation has been prepared and produced by BioArctic AB (publ) ( BioArctic ) solely for
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 3Q 2018 EARNINGS PRESENTATION NOVEMBER 2018 1 Forward-looking statements disclosure This presentation
More informationCorporate Overview May 8, 2014
0 Corporate Overview May 8, 2014 NASDAQ: CRIS Forward Looking Statements This presentation contains statements about Curis future expectations, plans and prospects that constitute forward-looking statements
More informationCorporate Presentation
Corporate Presentation Disclaimer Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the safe harbor provisions of the Private
More informationCalliditas Therapeutics Q2 Report Webcast August 16, 2018, 10:00 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO
Calliditas Therapeutics Q2 Report 2018 Webcast August 16, 2018, 10:00 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO Disclaimer Important information This presentation may contain certain
More informationLeerink Immuno-Oncology Roundtable Conference
Leerink Immuno-Oncology Roundtable Conference September 28, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private
More informationREWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES
REWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES May 18, 2017 Molecularly Defined Solid Tumor Program Update FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations,
More informationBuilding a Premier Oncology Biotech
Wells Fargo Securities Healthcare Conference Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO September 2018 Forward-Looking Statements All of the statements in this presentation
More informationStifel Healthcare Conference John Scarlett, M.D. Chief Executive Officer November 19, 2014
Stifel Healthcare Conference 2014 John Scarlett, M.D. Chief Executive Officer November 19, 2014 1 forward-looking statements Except for statements of historical fact, the statements during this presentation
More informationASCEND Phase 2 Trial of AXS-05 in MDD Topline Results Conference Call
NASDAQ: AXSM ASCEND Phase 2 Trial of in MDD Topline Results Conference Call January 7, 2019 Overview in MDD ASCEND Phase 2 Trial Topline Results Introduction Mark Jacobson, Senior Vice President, Operations
More information35 th Annual J.P. Morgan Healthcare Conference
35 th Annual J.P. Morgan Healthcare Conference Forward Looking Statement This presentation includes forward-looking statements. All statements, other than statements of historical facts, regarding management's
More informationCorporate Presentation: Jefferies Global Healthcare Conference June 7, 2018
Corporate Presentation: Jefferies Global Healthcare Conference June 7, 2018 2018 CytomX Therapeutics, Inc. 1 Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation
More informationThird Quarter 2015 Earnings Call. November 9, 2015
Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements
More informationPATENCY-1 Top-Line Results
PATENCY-1 Top-Line Results December 13, 2016 2016 Proteon Therapeutics, Inc. Cautionary Note Regarding Forward-Looking Statements This presentation contains statements that are, or may be deemed to be,
More informationMerck Announces FDA Approval of KEYTRUDA. Provided to Investors as a Reference
Merck Announces FDA Approval of KEYTRUDA Provided to Investors as a Reference Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationLehman Brothers Eighth Annual Global Healthcare Conference March 30, 2005 Bruce A. Peacock President and Chief Executive Officer
Lehman Brothers Eighth Annual Global Healthcare Conference March 30, 2005 Bruce A. Peacock President and Chief Executive Officer 2005 Adolor Corporation. All rights reserved. Safe Harbor Statement This
More information33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO Forward-Looking Statements This presentation,
More informationDawson James Conference
Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding
More informationVAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients. September 2018
VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients September 2018 Forward-Looking Statements Any statements contained in this presentation that do not describe historical facts may
More informationJP Morgan Healthcare Conference. January 8, 2007
JP Morgan Healthcare Conference January 8, 2007 Safe Harbor Statement Except for the historical information set forth herein, the matters set forth in this presentation,including without limitation statements
More informationCorporate Overview. February 2018 NASDAQ: CYTR
Corporate Overview February 2018 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER
More informationCorporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation May 2016 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary contain
More informationNASDAQ: ZGNX. Company Presentation. October 2017
NASDAQ: ZGNX Company Presentation October 2017 2 Forward Looking Statement Zogenix cautions you that statements included in this presentation that are not a description of historical facts are forward-looking
More informationPROMISE 1 Top-Line Data Results. June 27, 2017
PROMISE 1 Top-Line Data Results dd June 27, 2017 Forward Looking Statements This presentation and the accompanying commentary contains certain forward-looking statements within the meaning of Section 27A
More informationProsensa Corporate Overview Jefferies Healthcare Conference London, UK November 19, Hans Schikan, CEO
Prosensa Corporate Overview Jefferies Healthcare Conference London, UK November 19, 2014 Hans Schikan, CEO Forward-Looking Statements This presentation may contain statements that constitute forward-looking
More informationCredit Suisse 27 th Annual Healthcare Conference
CHANGING THE COURSE OF HUMAN HEALTH THROUGH BOLD PURSUITS IN SCIENCE Credit Suisse 27 th Annual Healthcare Conference November 14, 2018 Forward-Looking Statements and Adjusted Financial Information This
More informationMarch Corporate Presentation
March 2017 Corporate Presentation Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements
More informationCapricor Therapeutics
Therapeutics Conference Call to Discuss the HOPE-2 Clinical Trial NASDAQ: CAPR November 29, 2017 Forward-Looking Statements Statements in this presentation regarding the efficacy, safety, and intended
More informationAugust 7, Q Financial Results
August 7, 2018 Q2 2018 Financial Results 1 Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Steve Kanes, M.D., Ph.D., Chief Medical Officer
More informationJefferies 2015 Global Healthcare Conference June 1, 2015
Jefferies 2015 Global Healthcare Conference June 1, 2015 Page 0 Acceleron Forward-Looking Statements This presentation contains forward-looking statements. Forward-looking statements are neither historical
More informationCorporate Overview. July 2016 NASDAQ: CYTR
Corporate Overview July 2016 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES ASSOCIATED WITH A DEVELOPMENT-STAGE
More informationTargeted Therapeutics for Inflammatory Disease Jefferies Healthcare Conference
Targeted Therapeutics for Inflammatory Disease 2016 Jefferies Healthcare Conference Forward Looking Statements / Safe Harbor This presentation and the accompanying oral commentary contain forward-looking
More informationCloudbreak. March Cidara Therapeutics
Cloudbreak March 2019 Cidara Therapeutics 2019 0 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities
More informationPROMISE 2 Top-Line Data Results January 8, 2018
PROMISE 2 Top-Line Data Results January 8, 2018 Forward-Looking Statements This presentation and the accompanying commentary contains certain forward-looking statements within the meaning of Section 27A
More informationTargeting and Treating Cancer
Targeting and Treating Cancer Mark R. Baker, Chief Executive Officer Jefferies 2016 DISCLOSURE NOTICE This presentation may contain projections and other forward-looking statements regarding future events.
More informationCloudbreak. January Cidara Therapeutics
Cloudbreak January 2019 Cidara Therapeutics 2019 0 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities
More informationCAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month
More informationPSMA-617 License Transaction. October 2, 2017
PSMA-617 License Transaction October 2, 2017 Forward Looking Statements Certain of the statements made in this presentation are forward looking, such as those, among others, relating to future spending,
More informationSanthera to Acquire Option from Idorsia for Exclusive Sub-License to First-in-class Dissociative Steroid Vamorolone. Webcast, 21 November 2018
Santhera to Acquire Option from Idorsia for Exclusive Sub-License to First-in-class Dissociative Steroid Vamorolone Webcast, 21 November 2018 Disclaimer This presentation is not and under no circumstances
More informationSumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company)
December 21, 2016 Sumitomo Dainippon Pharma Co., Ltd. Sumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company) Sumitomo Dainippon Pharma Co., Ltd. (Head office: Osaka,
More informationTheravance Announces Positive Results from Phase 1 and Phase 2 Clinical Studies with TD-1211 in Development for Opioid-Induced Constipation
Theravance Announces Positive Results from Phase 1 and Phase 2 Clinical Studies with TD-1211 in Development for Opioid-Induced Constipation TD-1211 Achieves Primary and Secondary Endpoints SOUTH SAN FRANCISCO,
More informationPositioned for Growth
Positioned for Growth Annual Shareholders Meeting July 21, 2016 Paris Panayiotopoulos President and Chief Executive Officer David Sachs Non small cell lung cancer ARIAD clinical trial patient This presentation
More informationIntercell and Novartis form world leading strategic partnership to drive vaccines innovation
Intercell and Novartis form world leading strategic partnership to drive vaccines innovation Alliance creates opportunity for two strong innovators to combine development efforts in attractive areas Intercell
More informationCorporate Presentation March 2016
Corporate Presentation March 2016 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationInnovative Therapeutics for Orphan Liver Disease
Innovative Therapeutics for Orphan Liver Disease Note Regarding Forward-Looking Statements Certain statements in this presentation constitute forward-looking statements within the meaning of the Securities
More informationUpdate on Treatments for Systemic Amyloidosis
Update on Treatments for Systemic Amyloidosis Laura M. Dember, M.D. Renal, Electrolyte and Hypertension Division University of Pennsylvania ANZSN Update Course Darwin, Australia September 2, 2017 Disclosure
More information